# US 2025/0082685 A1 · Methods for attenuating viral infection and for treating lung injury

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082685 A1
- Document ID: US20250082685A1
- Status: Published application
- Kind: A1
- Application number: 18/808,956
- Filed: 2024-08-19
- Published: 2025-03-13
- Earliest claimed: 2019-06-06
- Assignees: Spiritus Therapeutics, Inc.
- Applicants: Spiritus Therapeutics, Inc.
- Inventors: Jodi Gurney; Robin Smith
- Web page: https://patentgrep.com/patent/US20250082685A1

## CPC

- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 11/00: Drugs for disorders of the respiratory system
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12N 2310/113: targeting other non-coding nucleic acids, e.g. antagomirs
- C12N 2310/141: MicroRNAs, miRNAs
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/158: Expression markers
- C12Q 2600/178: miRNA, siRNA or ncRNA
- G01N 2800/12: Pulmonary diseases
- G01N 2800/56: Staging of a disease; Further complications associated with the disease
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The described invention provides compositions and methods for treating a susceptible subject at risk of pulmonary complications of an acute lung injury caused by a severe infection with a respiratory virus and for restoring lung function to donor lungs. The methods include administering a therapeutic amount of a pharmaceutical composition comprising extracellular vesicles (EVs) comprising one or more miRNAs and a pharmaceutically acceptable carrier. The population of EVs can be derived from a patient who has recovered from an infection with the respiratory virus or has been exposed to anti-viral antibodies through treatment, can be derived from MSCs of a normal healthy individual, can be modified by a viral vector, or can be synthetic.

## Claims

### Claim 1

A precision medicine method for optimizing therapeutic benefit for a susceptible subject at risk of a chronic complication of an acute acute injury to a tissue, organ or system caused by a severe infection with a respiratory virus, comprising:
(a) obtaining a sample from a body fluid of the subject and from a healthy control;
(b) isolating EVs from the sample obtained from the body fluid of the subject and from the body fluid of the healthy control;
(c) measuring a level of expression of each of a plurality of miRNAs in the EVs from the sample obtained from the body fluid of the subject and in the EVs from the sample obtained from the body fluid of the healthy control;
(d) determining that expression of the one or more of the miRNAs in the EVs from the subject is dysregulated compared to the healthy control;
(e) identifying a predisposition to develop chronic complications of the acute injury:
(1) when the presence of one or more dysregulated miRNAs in the EVs from the sample obtained from the body fluid of the subject is detected;
(2) when an increase in levels of one or more WNT proteins in the EVs from the sample obtained from the body fluid of the subject compared to the control is detected; or
(3) when the presence of one or more dysregulated miRNAs and an increase in levels of one or more WNT proteins in the EVs from the sample obtained from the body fluid of the subject compared to the body fluid obtained from the control is detected; and
(f) tailoring a medical treatment that delays development of the chronic complications.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the medical treatment comprises: administering a therapeutic amount of a pharmaceutical composition comprising either:
(i′) at least about 1×108 whole MSCs comprising synthetic exosomes comprising a therapeutic amount of an miR-29a mimic, an miR-199-3p inhibitor, or both to the diagnosed subject; or
(ii′) a therapeutic amount of a purified and enriched population of synthetic exosomes comprising one or more of an miR-29a derived from normal healthy MSCs, an miR-29a mimic, an miR-199-3p inhibitor, to the diagnosed subject; or
(iii′) a therapeutic amount of a purified and enriched population of exosomes derived from a patient who has recovered from an infection with the respiratory virus or has been exposed to anti-viral antibodies through treatment;
wherein the therapeutic amount upregulates expression of miR-29a, downregulates expression of miR-199-3p, or both, and effectively delays development of the pulmonary complications.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the administering is by inhalation.

### Claim 4 (depends on 2)

The method according to claim 2, wherein the population of EVs is derived from peripheral blood mononuclear cells (PBMCs) of the recovered patient.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the PBMCs comprise T lymphocytes, B lymphocytes and NK cells.

### Claim 6 (depends on 2)

The method according to claim 2 wherein the population of EVs is derived from T lymphocytes of the recovered patient.

### Claim 7 (depends on 2)

The method according to claim 2, wherein the population of EVs is derived from B lymphocytes of the recovered patient.

### Claim 8 (depends on 2)

The method according to claim 2, wherein the population of EVs is derived from NK cells of the recovered patient.

### Claim 9 (depends on 2)

The method according to claim 2, wherein the population of EVs is obtained from the body fluid of the recovered patient.

### Claim 10 (depends on 2)

The method according to claim 2, wherein the population of EVs is modified by a viral vector.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the body fluid is peripheral blood, umbilical cord blood, or amniotic fluid.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the chronic complication comprises an inflammatory immune response that reduces function of the tissue, organ or system compared to a healthy control.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the tissue includes a joint tissue, bone marrow, brain tissue, eye tissue, intestinal tissue, peritoneal and retroperitoneal tissue pancreatic tissue, and skin.

### Claim 14 (depends on 1)

The method according to claim 1, wherein isolating step (b) comprises purifying the exosomes obtained from the body fluid by one or more of: a) ultracentrifugation; b) sucrose density gradient centrifugation; c) column chromatography; d) size exclusion; or e) filtration through a device containing an affinity matrix selective towards the EVs.

### Claim 15 (depends on 1)

The method according to claim 1, wherein the EVs obtained from the body fluid are characterized by sedimentation at about 100,000×g, a buoyant density in sucrose of about 1.10-1.21 g/ml, and an average diameter of from about 30 nm to about 200 nm.

### Claim 16 (depends on 1)

The method according to claim 1, wherein the average diameter of the EVs ranges from about 140 nm to about 150 nm.

### Claim 17 (depends on 1)

The method according to claim 1, wherein the EVs comprise microvesicles whose diameter is >200 nm.

### Claim 18 (depends on 1)

The method according to claim 1, wherein the predisposition to develop a fibrotic disease comprises onset of pulmonary fibrosis at an age earlier than the healthy control; typical predispositions based on genetic, environmental and lifestyle factors if not for the respiratory virus infection, or both.

### Claim 19 (depends on 1)

The method according to claim 1, wherein the susceptible subject includes a very young individual, an elderly individual, an individual who is suffering from a respiratory disease; an individual who is receiving immunosuppressant therapy; an individual with a long term health condition; and an individual who is physically weak due to malnutrition or dehydration.

### Claim 20 (depends on 1)

The method according to claim 1, wherein the severe infection with the respiratory virus comprises an acute lung injury, acute respiratory distress syndrome, or both; an acute kidney injury (AKI); hematological abnormalities; radiological abnormalities; or a combination thereof.

### Claim 21 (depends on 1)

The method according to claim 1, wherein the severe infection is caused by a respiratory virus selected from the group consisting of human coronavirus; human influenza, human herpesvirus, hantavirus; human cytomegalovirus; and human immunodeficiency virus.

### Claim 22 (depends on 1)

The method according to claim 1, wherein the dysregulated miRNAs comprise one or more of miR-134-5p, miR-196b-5p, miR-629-5p, miR-206, miR-192-5p, miR-320c, miR-125a-3p, miR-215-5p, miR-642a-3p, miR-576-3p, miR-3679-5p, miR-134-5p, miR-196b-5p, miR-629-5p, or miR-206. miR-let7 d; miR-29a, miR 20-b, miR-29c, or miR-199.

### Claim 23 (depends on 1)

The method according to claim 1, wherein the miRNA is downregulated compared to the healthy control.

### Claim 24 (depends on 1)

The method according to claim 1, wherein the miRNA is upregulated compared to the healthy control.

### Claim 25 (depends on 1)

The method according to claim 1, further comprising detecting a level of expression of a WNT protein in the sample comprising EVs obtained from the body fluid; and determining that expression of one or more of the WNT proteins in the sample comprising EVs obtained from the body fluid of the subject is dysregulated compared to the healthy control.

### Claim 26 (depends on 25)

The method of claim 25, wherein the WNT protein comprises WNT-5A.

### Claim 27 (depends on 1)

The method according to claim 1, further comprising
(a) obtaining a blood or serum sample from the subject and from the healthy control;
(b) detecting a level of expression of one or more biomarkers selected from KL-6/MUC1, SP-A, SP-D, CCL18, MMP-1, and MMP-7 in the samples; and
(c) comparing the levels of expression of the one or more biomarkers in the samples from the subject and from the healthy control;
wherein
an increase in the levels of the one or more biomarkers in the sample from the subject compared to the healthy control indicates a poor prognosis in the subject; and
a decrease in the levels of the one or more biomarkers in the sample from the susceptible subject compared to the healthy control indicates a positive prognosis for the susceptible subject.

### Claim 28 (depends on 25)

The method according to claim 25, further comprising obtaining a bronchoalveolar lavage fluid (BALF) sample from the subject and from the healthy control; isolating EVs from the BALF samples; detecting a level of expression of one or more WNT proteins in the EVs; and comparing the level of expression of the WNT protein in the EVs from the subject and from the healthy control; wherein an increase in the levels of the one or more WNT proteins in the EVs from the subject indicates the subject has a fibrotic disease.

### Claim 29

(canceled)

### Claim 30 (depends on 2)

The method according to claim 2, wherein the miR-29a mimic has at least about 70% sequence homology with SEQ ID NO: 1.

### Claim 31 (depends on 2)

The method according to claim 2, wherein the miR-199-3p inhibitor has at least about 70% sequence homology with SEQ ID NO: 2.

### Claim 32

A method of diagnosing and treating a subject at risk of a chronic complication of an acute injury to a tissue, organ or system caused by a severe infection with a respiratory virus in a susceptible subject comprising
(a) obtaining a sample of a body fluid from the subject and from a healthy control;
(b) isolating EVs from the sample obtained from the body fluid of the subject and of the healthy control;
(c) detecting a level of expression of miRNAs in the EVs from the sample obtained from the body fluid of the subject and in the EVs from the sample obtained from the body fluid of the healthy control;
(d) determining that expression of one or more of the miRNAs in the EVs from the subject is dysregulated compared to the healthy control; and
(e) identifying the subject as one that can benefit therapeutically from being treated to reduce risk of the chronic complication:
(i) when the presence of one or more dysregulated miRNAs in the EVs in the sample of the body fluid obtained from the subject is detected;
(ii) when an increase in levels of one or more WNT proteins in the EVs from the sample of the body fluid obtained from the subject compared to the healthy control is detected; or
(iii) when the presence of one or more dysregulated miRNAs and an increase in levels of one or more WNT proteins in the EVs from the urine sample from the subject compared to the healthy control is detected; and
(f) administering a therapeutic amount of a pharmaceutical composition comprising either:
(i′) at least about 1×108 whole mesenchymal stem cells (MSCs) comprising synthetic exosomes comprising a therapeutic amount of an miR-29a derived from normal healthy MSCs, an miR-29a mimic, an miR-199-3p inhibitor, or both to the diagnosed subject; or
(ii′) a therapeutic amount of a purified and enriched population of synthetic exosomes comprising one or more of an miR-29a derived from normal healthy MSCs, an miR-29a mimic, an miR-199-3p inhibitor, to the diagnosed subject;
wherein the therapeutic amount upregulates expression of miR-29a, downregulates expression of miR-199-3p, and delays development of the chronic complication.

### Claim 33 (depends on 32)

The method according to claim 32, wherein the administering is by inhalation.

### Claim 34 (depends on 32)

The method according to claim 32, wherein the sequence of the miR-29a mimic is at least about 70% homologous with SEQ ID NO: 1.

### Claim 35 (depends on 32)

The method according to claim 32, wherein the sequence of the miR-199-3p inhibitor is at least about 70% homologous with SEQ ID NO: 2.

### Claim 36 (depends on 32)

The method according to claim 32, wherein the upregulated expression of miR-29a decreases expression of MMP-2.

### Claim 37 (depends on 32)

The method according to claim 32, wherein the downregulated expression of miR-199-3p upregulates CAV-1 expression, which is antifibrotic.

### Claim 38 (depends on 32)

The method according to claim 32, wherein the body fluid is peripheral blood, umbilical cord blood, or amniotic fluid.

### Claim 39 (depends on 32)

The method according to claim 32, wherein the chronic complication comprises an inflammatory immune response that recues function of the tissue, organ or system compared to the tissue, organ or system of a healthy control.

### Claim 40 (depends on 39)

The method according to claim 39 wherein the tissue includes a joint tissue, bone marrow, brain tissue, eye tissue, intestinal tissue, peritoneal and retroperitoneal tissue, pancreatic tissue and skin.

### Claim 41

A method of attenuating a severe infection with a respiratory virus in a susceptible subject and reducing risk of a chronic complication of the severe infection comprising administering to the subject a therapeutic amount of a pharmaceutical composition comprising a population of EVs comprising one or more of an miRNA derived from normal, healthy MSCs, an miR-29a mimic, an miR-199-3p inhibitor, and a pharmaceutically acceptable carrier, and wherein the pharmaceutical composition upregulates expression of miR-29a, downregulates miR-199-3p, or both, wherein the chronic complication comprises an inflammatory immune response that reduces function of the tissue, organ or system of the subject compared to a healthy control; and
wherein the method delivers the EVs comprising miRNAs to the tissue, organ or system of the subject at risk and attenuates the severe infection and attenuates the risk of the chronic complication of the severe infection by modulating the inflammatory immune response.

### Claim 42 (depends on 41)

The method according to claim 41, wherein the susceptible subject includes a very young individual, an elderly individual, an individual who is suffering from a respiratory disease; an individual who is receiving immunosuppressant therapy; an individual with a long term health condition; and an individual who is physically weak due to malnutrition or dehydration.

### Claim 43 (depends on 41)

The method according to claim 41, wherein the population of EVs is derived from a patient who has recovered from an infection with a respiratory virus or has been exposed to anti-viral antibodies through treatment.

### Claim 44 (depends on 43)

The method according to claim 43, wherein the population of EVs is derived from peripheral blood mononuclear cells (PBMCs) of the recovered patient.

### Claim 45 (depends on 43)

The method according to claim 43, wherein the PBMCs comprise T lymphocytes, B lymphocytes and NK cells.

### Claim 46 (depends on 43)

The method according to claim 43, wherein the population of EVs is derived from T lymphocytes of the recovered patient.

### Claim 47 (depends on 43)

The method according to claim 43, wherein the population of EVs is derived from B lymphocytes of the recovered patient.

### Claim 48 (depends on 43)

The method according to claim 43, wherein the population of EVs is derived from NK cells of the recovered patient.

### Claim 49 (depends on 43)

The method according to claim 43, wherein the population of EVs is obtained-from a eukaryotic plant or is synthetic.

### Claim 50 (depends on 43)

The method according to claim 43, wherein the population of EVs is modified by a viral vector.

### Claim 51 (depends on 43)

The method according to claim 43, wherein the respiratory virus is selected from the group consisting of human coronavirus; human influenza, human herpesvirus, hantavirus; human cytomegalovirus; and human immunodeficiency virus.

### Claim 52

(canceled)

### Claim 53

(canceled)

### Claim 54 (depends on 41)

The method according to claim 41, wherein attenuating the chronic complication accomplishes one or more of decreasing one or more symptoms of a fibrotic lung disease, restoring tissue, organ or system function, reducing or eliminating a need for other active agents or therapeutics; and slowing progression of a fibrotic lung disease.

### Claim 55

(canceled)

### Claim 56

(canceled)

### Claim 57

(canceled)

### Claim 58 (depends on 41)

The method according to claim 41, wherein the method treats progression to a fibrotic disease.

### Claim 59 (depends on 57)

The method according to claim 57 wherein the fibrotic lung disease is pulmonary fibrosis.

### Claim 60 (depends on 41)

The method according to claim 41, wherein the upregulated expression of miR-29a decreases expression of MMP-2.

### Claim 61 (depends on 41)

The method according to claim 41, wherein the downregulated expression of miR-199-3p upregulates CAV-1 expression, which is antifibrotic.

### Claim 62 (depends on 41)

The method according to claim 41, wherein the miR-29a mimic has at least about 70% sequence homology with SEQ ID NO: 1.

### Claim 63 (depends on 41)

The method according to claim 41, wherein the miR-199-3p inhibitor has at least about 70% sequence homology with SEQ ID NO: 2.

### Claim 64 (depends on 41)

The method according to claim 41, wherein the normal healthy MSCs are obtained from a human subject.

### Claim 65 (depends on 41)

The method according to claim 41, wherein
(a) the MSCs are obtained from a body fluid selected from the group consisting of peripheral blood, umbilical cord blood, and amniotic fluid; or
(b) the MSCs are derived from a tissue selected from the group consisting of an amniotic membrane, a chorionic membrane, an umbilical cord tissue, bone marrow, and adipose tissue.

### Claim 66 (depends on 41)

The method of claim 41, wherein the EVs are characterized by sedimentation at about 100,000×g, a buoyant density in sucrose of about 1.10-1.21 g/ml, and an average diameter of from about 30 nm to about 200 nm.

### Claim 67 (depends on 41)

The method according to claim 41, wherein the average diameter of the EVs ranges from about 140 nm to about 150 nm.

### Claim 68 (depends on 41)

The method according to claim 41, wherein the administering occurs nasally, intratracheally, orally, parenterally, topically, or by inhalation.

### Claim 69 (depends on 41)

The method according to claim 41, wherein the administering occurs by inhalation.

### Claim 70 (depends on 41)

The method according to claim 41, wherein the pharmaceutical composition further comprises at least one additional therapeutic agent.

### Claim 71 (depends on 69)

The method according to claim 69, wherein the additional therapeutic agent is selected from one or more of an immunomodulatory agent, an analgesic agent, an anti-inflammatory agent, an anti-infective agent, an anti-malarial agent, an anti-viral agent, an anti-fibrotic agent, or a proton pump inhibitor.

### Claim 72 (depends on 70)

The method according to claim 70, wherein the immunomodulatory agent is a corticosteroid.

### Claim 73 (depends on 71)

The method according to claim 71, wherein the corticosteroid is selected from prednisone, azathioprine, mycophenolate, mycophenolate mofetil, colchicine, interferon-gamma 1b, and combinations thereof.

### Claim 74 (depends on 70)

The method according to claim 70, wherein the analgesic agent is selected from codeine, hydrocodone, oxycodone, methadone, hydromorphone, morphine, fentanyl, and combinations thereof.

### Claim 75 (depends on 70)

The method according to claim 70, wherein the anti-inflammatory agent is selected from aspirin, celecoxib, diclofenac, diflunisal, etodolac, ibuprofen, indomethacin, ketoprofen, ketorolac nabumetone, naproxen, nintedanib, oxaprozin, pirfenidone, piroxicam, salsalate, sulindac, tolmetin, and combinations thereof.

### Claim 76 (depends on 70)

The method according to claim 70, wherein the anti-viral agent is selected from acyclovir, gancidovir, foscarnet; ribavirin; amantadine, azidodeoxythymidine/zidovudine), nevirapine, tetrahydroimidazobenzodiazepinone (TIBO) compound; efavirenz; remdecivir, and delavirdine.

### Claim 77 (depends on 70)

The method according to claim 70, wherein the anti-malarial agent is selected from an aryl aminoalcohol compound selected from quinine, quinidine, chloroquine, amodiaquine, mefloquine, halofantrine, lumefantrine, piperaquine, tafenoquine; an antifolate compound, selected from pyrimethamine, proguanil, chlorproguanil, trimethoprim; an artemisinin compound selected from artemisinin, dihydroartemisinin, artemether, artesunate; atovaquone.

### Claim 78 (depends on 70)

The method according to claim 70, wherein the anti-infective agent is selected from amoxicillin, doxycycline, demeclocycline; eravacycline, minocycline, ormadacycline, tetracycline, cephalexin, defotaxime, cetazidime, cefuroxime, ceftaroline; ciprofloxacin, levofloxacin, moxifloxacin clindamycin, lincomycin, metronidazole, azithromycin; clarithromycin, erythromycin, sulfamethoxazle and trimethoprim; sulfasalazine, amoxicillin and clavulanate; vancomycin, dalbavancin, oritavancin, telavancin, gentamycin, tobramycin, amikacin, imipenem and cilastatin, meropenem, doripenem, and ertapenem.

### Claim 79 (depends on 70)

The method according to claim 70, wherein the anti-fibrotic agent is selected from nintedanib, pirfenidone, and combinations thereof.

### Claim 80 (depends on 70)

The method according to claim 70, wherein the proton pump inhibitor is selected from omeprazole, lansoprazole, dexlansoprazole, esomeprazole, pantoprazole, rabeprazole, ilaprazole, and combinations thereof.

### Claim 81 (depends on 41)

The method of claim 41, further comprising:
(a) Obtaining a sample of a body fluid from the subject and from a healthy control;
(b) Isolating extracellular vesicles (EVs) from the sample of the body fluid obtained from the subject and the healthy control;
(c) Measuring a level of expression of one or more Idiopathic Pulmonary Fibrosis (IPF) markers selected from the group consisting of integrin mRNA, collagen type 1α1 mRNA, miR29, c-jun protein; estrogen receptor alpha (ERα), androgen receptor (AR), caveollin-1 protein; pAKT/AKT protein in the EVs obtained from the subject and from the healthy control prior to treatment; and
(d) treating the subject by administering a pharmaceutical composition comprising a therapeutic amount of EVs purified from the healthy control; wherein the therapeutic amount modulates the level of expression of the one or more IPF markers in the body fluid of the subject.

### Claim 82

A method for resuscitating donor lungs comprising administering ex vivo a therapeutic amount of a pharmaceutical composition comprising a population of EVs comprising one or more of an miRNA derived from normal, healthy MSCs, an miR-29a mimic, an miR-199-3p inhibitor, and a pharmaceutically acceptable carrier, and wherein the pharmaceutical composition upregulates expression of miR-29a, downregulates miR-199-3p, or both, wherein the method restores lung function.

### Claim 83 (depends on 81)

The method of claim 81, wherein the exosomes are derived from a patient who has recovered from an infection with a respiratory virus or has been exposed to anti-viral antibodies through treatment.

### Claim 84 (depends on 82)

The method of claim 82, wherein the population of EVs is derived from peripheral blood mononuclear cells (PBMCs) of the recovered patient.

### Claim 85 (depends on 83)

The method of claim 83, wherein the PBMCs comprise T lymphocytes, B lymphocytes and NK cells.

### Claim 86 (depends on 82)

The method of claim 82, wherein the population of EVs is derived from T lymphocytes of the recovered patient.

### Claim 87 (depends on 82)

The method of claim 82, wherein the population of EVs is derived from B lymphocytes of the recovered patient.

### Claim 88 (depends on 82)

The method of claim 82, wherein the population of EVs is derived from NK cells of the recovered patient.

### Claim 89 (depends on 82)

The method of claim 82, wherein the population of EVs is derived from urine of the recovered patient.

### Claim 90 (depends on 82)

The method of claim 82, wherein the population of EVs is modified by a viral vector.

### Claim 91 (depends on 82)

The method of claim 82, wherein the exosomes are derived from a eukaryotic plant or are synthetic.

### Claim 92 (depends on 12)

The method according to claim 12, wherein the organ or system includes a renal system, heart/cardiovascular system, hepatic system pulmonary system, or a combination thereof.

### Claim 93 (depends on 91)

The method according to claim 91, wherein
the reduced function of the cardiac system comprises cardiac remodeling progressing to a cardiac fibrosis; or
the reduced function of the hepatic system comprises hepatic inflammation progressing to a hepatic fibrosis; or
the reduced function of the renal system comprises glomerular inflammation progressing to a renal fibrosis; or
the reduced function of the pulmonary system comprises an acute pulmonary injury comprising inflammation progressing to a fibrotic lung disease; or
a combination thereof.

### Claim 94 (depends on 33)

The method according to claim 33, wherein the organ or system includes a renal system, heart/cardiovascular system, hepatic system pulmonary system, or a combination thereof.

### Claim 95 (depends on 93)

The method according to claim 93, wherein
the reduced function of the cardiac system comprises cardiac remodeling progressing to a cardiac fibrosis; or
the reduced function of the hepatic system comprises hepatic inflammation progressing to a hepatic fibrosis; or
the reduced function of the renal system comprises glomerular inflammation progressing to a renal fibrosis; or
the reduced function of the pulmonary system comprises an acute pulmonary injury comprising inflammation progressing to a fibrotic lung disease; or
a combination thereof.
